The National Medical Journal of India

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 33  |  Issue : 5  |  Page : 271--275

Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India


Sushmita Pathy1, Bhanu Prasad Venkatesulu1, Supriya Mallick1, Suryanarayana S.V. Deo2, Bidhu Kalyan Mohanti1 
1 Department of Radiation Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
2 Department of Surgical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India

Correspondence Address:
Sushmita Pathy
Department of Radiation Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029
India

Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid. Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome. Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30–85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9–52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06). Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.


How to cite this article:
Pathy S, Venkatesulu BP, Mallick S, Deo SS, Mohanti BK. Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India.Natl Med J India 2020;33:271-275


How to cite this URL:
Pathy S, Venkatesulu BP, Mallick S, Deo SS, Mohanti BK. Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India. Natl Med J India [serial online] 2020 [cited 2021 Jun 19 ];33:271-275
Available from: http://www.nmji.in/article.asp?issn=0970-258X;year=2020;volume=33;issue=5;spage=271;epage=275;aulast=Pathy;type=0